Maravai LifeSciences (NASDAQ:MRVI) Announces Earnings Results, Beats Estimates By $0.03 EPS

Maravai LifeSciences (NASDAQ:MRVI) announced its quarterly earnings data on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03, FiscalAI reports. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%.The firm had revenue of $49.87 million during the quarter, compared to analyst estimates of $49.06 million.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• The company returned to positive adjusted EBITDA in Q4 with $0.536M, exceeded its cost-savings target (now > $65M annualized), and made a voluntary $50M debt repayment in Q1 2026 to reduce interest expense.
• 2026 guidance targets meaningful improvement — revenue of $200M–$210M (up 8%–13%) and adjusted EBITDA of $18M–$20M, with forecasted ~1,200 bps gross margin expansion and ~13% lower operating expenses.
• Commercial and product momentum at TriLink and Cygnus — strong demand for GMP consumables and CDMO services, early traction for ModTail and mRNA Builder, > $1.2M of GMP enzyme orders in hand for 2026, and Cygnus’s high-margin HCP kits plus growing MockV/MachV services expanding analytical offerings.
• GAAP results remain weak due to non-cash charges — Q4 GAAP net loss was $63M (including a $25.8M intangible impairment and $12.1M restructuring), full-year GAAP loss $230.8M, and Q4 operating cash outflow was $22.8M, with long-term debt of $294.2M before the voluntary repayment.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI traded up $0.14 during trading on Wednesday, hitting $3.26. 693,854 shares of the company traded hands, compared to its average volume of 1,061,144. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. The business’s fifty day moving average is $3.44 and its 200-day moving average is $3.19. The stock has a market capitalization of $833.61 million, a price-to-earnings ratio of -3.88 and a beta of 0.39. Maravai LifeSciences has a one year low of $1.66 and a one year high of $4.11.

Insider Transactions at Maravai LifeSciences

In related news, Director Gregory T. Lucier acquired 51,472 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, December 5th. The stock was acquired at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the transaction, the director directly owned 106,595 shares of the company’s stock, valued at $394,401.50. This trade represents a 93.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC grew its position in shares of Maravai LifeSciences by 1,463.1% during the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock worth $841,000 after acquiring an additional 356,067 shares during the last quarter. Creative Planning boosted its stake in Maravai LifeSciences by 49.6% during the 2nd quarter. Creative Planning now owns 116,031 shares of the company’s stock valued at $280,000 after purchasing an additional 38,450 shares during the period. Rhumbline Advisers grew its position in Maravai LifeSciences by 20.3% in the 2nd quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock worth $471,000 after purchasing an additional 32,940 shares during the last quarter. Prudential Financial Inc. bought a new position in Maravai LifeSciences in the 2nd quarter worth about $36,000. Finally, Invesco Ltd. increased its stake in shares of Maravai LifeSciences by 16.8% in the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock valued at $680,000 after purchasing an additional 40,495 shares during the period. 50.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Wells Fargo & Company boosted their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a report on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.25.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.